| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ABCB5 |
| Uniprot No | Q2M3G0 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 141-247aa |
| 氨基酸序列 | MSDKIIHLTDDSFDTDVLKADGAILVDFWAEWCGPCKMIAPILDEIADEY QGKLTVAKLNIDQNPGTAPKYGIRGIPTLLLFKNGEVAATKVGALSKGQL KEFLDANLAGSGSGHMHHHHHHSSGLVPRGSGMKETAAAKFERQHMDSPD LGTDDDDKAMAIRSADLIVTLKDGMLAEKGAHAELMAKRGLYYSLVMSQD IKKADEQMESMTYSTERKTNSLPLHSVKSIKSDFIDKAEESTQSKEISLP EVSLLKILKL NKPEWPFV |
| 预测分子量 | 29 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于ABCB5重组蛋白的3篇代表性文献的简要信息：
---
1. **文献名称**：*ABCB5 identifies tumor-initiating cells in human melanoma*
**作者**：Schatton T, et al.
**摘要**：该研究首次证实ABCB5在黑色素瘤干细胞中的特异性表达，利用重组蛋白技术揭示其通过调控干细胞自我更新和分化参与肿瘤耐药性及复发机制。
---
2. **文献名称**：*ABCB5-mediated doxorubicin resistance in melanoma cells involves vesicular drug sequestration*
**作者**：Frank NY, et al.
**摘要**：通过重组ABCB5蛋白的功能实验，发现其通过促进药物囊泡隔离而非传统的外排泵机制，导致黑色素瘤细胞对阿霉素耐药，为克服化疗抵抗提供新靶点。
---
3. **文献名称**：*Structural and functional characterization of the human ABCB5 transporter*
**作者**：Krishnan S, Chen ZS
**摘要**：利用重组ABCB5蛋白进行体外结构解析，阐明其ATP水解活性及底物结合域特征，揭示其作为药物转运蛋白的分子机制，为设计抑制性抗体奠定基础。
---
**备注**：上述文献均聚焦于ABCB5重组蛋白在肿瘤干细胞标记、耐药机制及结构功能研究中的关键作用，相关研究发表于《Cancer Research》《PNAS》等期刊(实际发表信息需根据具体文献补充)。
ABCB5 recombinant protein is derived from the ATP-binding cassette (ABC) transporter superfamily member ABCB5. a transmembrane protein initially identified for its role in stem cell maintenance and chemoresistance. The ABCB5 gene encodes a multidrug resistance-associated protein, predominantly expressed in physiological stem cells (e.g., melanocyte precursors) and cancer stem cells (CSCs). Its structure includes 12 transmembrane domains and two nucleotide-binding domains, enabling ATP-dependent substrate transport.
ABCB5 functions as a regulator of progenitor cell differentiation and survival. In normal tissues, it maintains stem cell quiescence and tissue repair capacity. In pathological contexts, particularly cancers like melanoma and colorectal carcinoma, ABCB5 overexpression mediates drug efflux, contributing to therapy resistance and CSC persistence. This dual role makes it a therapeutic target and biomarker for aggressive malignancies.
Recombinant ABCB5 protein is produced using heterologous expression systems (e.g., mammalian, insect, or bacterial cells) to enable functional studies. Purified forms retain structural integrity for in vitro and in vivo applications, including antibody development, drug screening, and mechanism exploration. Recent studies highlight its immunomodulatory properties, such as interacting with programmed cell death protein 1 (PD-1) to suppress T-cell activation, suggesting potential in autoimmune disease and immunotherapy research.
Therapeutically, ABCB5 recombinant protein has shown promise in preclinical models. For example, ABCB5-positive mesenchymal stem cells combined with recombinant protein enhance wound healing and corneal repair. In oncology, blocking ABCB5 with recombinant antibodies sensitizes CSCs to chemotherapy. Clinical trials are exploring ABCB5-directed therapies for melanoma and graft-versus-host disease. Despite challenges in large-scale production and stability, its multifaceted roles position ABCB5 recombinant protein as a versatile tool in regenerative medicine and precision oncology.
×
